Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/9989
Citations | ||
Scopus | Web of ScienceĀ® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Post-inhalation bronchoconstriction by beclomethasone dipropionate: A comparison of two different CFC propellant formulations in asthmatics |
Author: | Ruffin, R. Campbell, D. Chia, M. |
Citation: | Respirology, 2000; 5(2):125-131 |
Publisher: | Blackwell Publishing Asia |
Issue Date: | 2000 |
ISSN: | 1323-7799 1440-1843 |
Statement of Responsibility: | Ruffin, Richard E. ; Campbell, Donald A. ; Chia, Mon M. |
Abstract: | <h4>Objective</h4>To assess the change in bronchial response to cumulative doses from two beclomethasone dipropionate metered-dose inhalers (MDI), each using chlorofluorocarbon (CFC) propellants, in asthma patients previously showing falls in forced expiratory volume in 1 s (FEV1) shortly after exposure to beclomethasone MDI.<h4>Methodology</h4>A total of 18 patients were randomized to a single-blind, three-period cross-over treatment regimen, whereby each was administered increasing doses of control mixture (containing surfactant and CFC propellants) or beclomethasone, formulated as either Becloforte or Respocort (250-1000 microg per dose; cumulative dose 2000 microg). Bronchial response was measured by comparison of FEV1 values pre- and post-inhalation.<h4>Results</h4>Respocort formulation produced the least post-dose mean maximum reduction in FEV1 (0.36 +/- 0.17 L; 14.3 +/- 7.2% of baseline FEV1), while the reduction caused by the control was similar (0.40 +/- 0.18 L; 16.2 +/- 9.9% of baseline FEV1). Becloforte produced a significantly greater maximum reduction in FEV1 than Respocort (0.55 +/- 0.32 L, P = 0.003; 22.0 +/- 15.3% of baseline FEV1, P = 0.005). No serious adverse events were reported, but four patients experienced falls in FEV1 of greater than 15% (three on Becloforte, one using the control).<h4>Conclusion</h4>The incidence of falls in FEV1 following use of beclomethasone MDI was low and generally not serious even in a selected population. The Becloforte preparation produced significantly more post-dose bronchoconstriction than the Respocort formulation, perhaps because of differences in the composition of the surfactant and/or CFC propellant mixtures used to formulate each of the aerosols. |
Keywords: | Humans Asthma Chlorofluorocarbons, Methane Beclomethasone Anti-Inflammatory Agents Anti-Asthmatic Agents Glucocorticoids Surface-Active Agents Forced Expiratory Volume Administration, Inhalation Administration, Topical Cross-Over Studies Single-Blind Method Bronchoconstriction Adult Aged Middle Aged Female Male |
DOI: | 10.1046/j.1440-1843.2000.00238.x |
Published version: | http://dx.doi.org/10.1046/j.1440-1843.2000.00238.x |
Appears in Collections: | Aurora harvest 4 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.